Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma

Allergy and Asthma Proceedings

Volumn 31, Issue 1, 2010, Pages 10-19

  Skoner, David P ^a,b   Gentile, Deborah A ^a,b   Angelini, Betty ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Asthma; AUC; Children; Cortisol; Cosyntropin; Hypothalamic pituitary axis; Inhaled corticosteroids; Mometasone furoate; Plasma cortisol; Urinary free cortisol

Indexed keywords

HYDROCORTISONE; MOMETASONE FUROATE; PLACEBO; TETRACOSACTIDE;

ABDOMINAL PAIN; ADRENAL SUPPRESSION; ALLERGY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESEARCH; DRUG RESPONSE; DRUG TOLERABILITY; DRUG URINE LEVEL; DRY POWDER; DYSPEPSIA; EDEMA; EPISTAXIS; EYE MALFORMATION; FEMALE; FEVER; HEARING IMPAIRMENT; HORMONE SYNTHESIS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSECT BITE; MAJOR CLINICAL STUDY; MALE; MILD INTERMITTENT ASTHMA; MUSCULOSKELETAL PAIN; OTALGIA; PHARYNGITIS; POWDER INHALER; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCHOOL CHILD; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; AREA UNDER CURVE; ASTHMA; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; PITUITARY-ADRENAL SYSTEM; PREGNADIENEDIOLS; TREATMENT OUTCOME;

EID: 76149099278     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2010.31.3305     Document Type: Article

References (19)

1. Akinbami L. The state of childhood asthma, United States, 1980-2005. Adv Data 381:1-24, 2006.
2. Global Initiative for Asthma. Global strategy for asthma management and prevention. Available online at www.ginaasthma.org; last accessed October 19, 2008.
3. National Asthma Education and Prevention Program. Expert panel report 3: Guidelines for the diagnosis and management of asthma. Available online at www.nhlbi.nih.gov/guidelines/ asthma/index.htm; last accessed April 16, 2008.
4. Skoner JD, Schaffner TJ, Schad CA, et al. Addressing steroid phobia: Improving the risk-benefit ratio with new agents. Allergy Asthma Proc 29:358-364, 2008.
5. Ricciardolo FL. The treatment of asthma in children: Inhaled corticosteroids. Pulm Pharmacol Ther 20:473-482, 2007.
6. Bensch GW, Prenner B, Berkowitz R, et al. Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann Allergy Asthma Immunol 96:533-540, 2006.
7. D'Urzo A, Karpel JP, Busse WW, et al. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin 21:1281-1289, 2005.
8. Berger WE, Milgrom H, Chervinsky P, et al. Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. Ann Allergy Asthma Immunol 97:672-680, 2006.
9. Meltzer EO, Baena-Cagnani CE, Chervinsky P, et al. Once-daily mometasone furoate administered by dry powder inhaler for the treatment of children with persistent asthma. Pediatr Asthma Allergy Immunol 20:67-81, 2007.
10. Schering Corp. Asmanex Twisthaler (mometasone furoate inhalation powder), full prescribing information. Kenilworth, NJ; January 2008.
11. Lemanske R, Lockey R, and Murphy K. Effects of one year of treatment with mometasone furoate metered dose inhaler (MF-MDI) on growth in children with asthma. Eur Respir J 24:378s, 2004 (Abs).
12. Skoner D, Dunn M, and Lee T. Effects of mometasone furoate dry powder inhaler on growth velocity and hypothalamic-pituitary-adrenal axis function in children with asthma. Am J Respir Crit Care Med 167:A272, 2003 (Abs).
13. Kannisto S, Korppi M, Remes K, et al. Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab 85:652-657, 2000.
14. Bernstein DI, Berkowitz RB, Chervinsky P, et al. Dose-ranging study of a new steroid for asthma: Mometasone furoate dry powder inhaler. Respir Med 93:603-612, 1999.
15. Affrime MB, Kosoglou T, Thonoor CM, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 118:1538-1546, 2000.
16. Fardon TC, Lee DK, Haggart K, et al. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 170:960-966, 2004.
17. Bernstein DI, and Allen DB. Evaluation of tests of hypothalamic -pituitary-adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol 98:118-127, 2007.
18. Lipworth BJ, and Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 52:476-482, 1997.
19. Skoner D, Angellini B, Gentile D, et al. Pediatric airflow profiles with the new mometasone furoate dry powder inhaler (MFDPI). J Allergy Clin Immunol 106:S16, 2000 (Abs).